 Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4 |
| The present invention provides DNA sequences encoding mammalian Interleukin-4 receptors (IL-4R) or ... |
|
| Surgical irrigation solution and method for inhibition of pain and inflammation |
| The present invention provides a solution constituting a mixture of multiple agents in low ... |
|
| Method of treatment of osteoarthritis with interleuken-1 receptor antagonist |
| OF THE INVENTION As indicated hereinabove, the present invention is directed to both a method and ... |
|
| Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints |
| The present invention has met the above described needs by providing methods for introducing at ... |
|
| Surgical irrigation solution and method for inhibition of pain and inflammation |
| The present invention provides a solution constituting a mixture of multiple agents in low ... |
|
| Surgical irrigation solution and method for inhibition of pain and inflammation |
| The present invention provides a solution constituting a mixture of multiple agents in low ... |
|
| Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| One embodiment of the present invention is hydrolyzed collagen type II, the hydrolyzed collagen ... |
|
| Method and compositions for identification of species in a sample using type II topoisomerase sequences |
| The invention comprises means to identify one or more species in a sample by selectively amplifying ... |
|
| Oxygen carrier system, artificial oxygen carrier, and reducing agent |
| OF THE INVENTION The present invention will be explained in detail below. The oxygen carrier ... |
|
|
Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
| Details |
Inventors: Hausman, Marvin S.;
Assignee:
Primary Examiner: Brown; Johnnie R.
Assistant Examiner:
Attorney, Agent or Firm: Mueth; Joseph E.
The administration of "active" chondroitin sulfate A (CSA), "active" chondroitin sulfate C (CSC), or mixtures thereof to mammals including humans suffering from cancer, bacterial infections, trauma, irritation, placement of foreign objects, tubes or instruments, or damage of the upper or lower urinary tract, and related transitional cell surfaces to prevent cancer cell implantation or adherence, bacterial infestation or adherence, trauma, irritation, or damage from placement of foreign objects, tubes or instruments in the kidney, renal pelvis, ureter, bladder, urethra and related transitional cell surfaces by the irrigation of said surfaces and/or tubes and instruments with a solution of said drugs or mixtures thereof. |
|
DETAILED DESCRIPTION I claim: 1.
The method which comprises the administration of "active" chondroitin sulfate A (CSA), "active" chondroitin sulfate C (CSC), or mixtures thereof to mammals including humans to the surfaces of the kidney, renal pelvis, ureter, bladder, urethra and related transitional cell surfaces by the irrigation of said surface with a solution of said drugs or mixtures thereof.
2.
The method of claim 1 wherein the drug is administered in an effective amount as an aqueous solution.
3.
The method of claim 1 wherein said drug is "active" chondroitin sulfate A (CSA).
4.
The method of claim 1 wherein said drug is "active" chondroitin sulfate C (CSC).
5.
The method of claim 1 wherein the irrigation mitigates against adhesion of E-Coli to the bladder surfaces.
6.
The method of claim 1 wherein the irrigation mitigates against the incidence of transitional cell carcinoma in the bladder.
Description:
BACKGROUND OF THE INVENTION The use of "active" chondroitin sulfate A and C (CSA and CSC), and mixtures of these drugs are known for use in the treatment of a variety of cardiovascular diseases and as preventative therapy for these diseases.
These drugs including their method of production are described in Morrison U.
S.
Pat.
Nos.
3,895,106 and 3,894,107 issued July 15, 1975.
An improved method for the production of these drugs is disclosed in Rucker U.
S.
patent application Ser.
No.
82,045, filed Oct.
5, 1979, now abandoned, and Rucker U.
S.
Pat.
No.
4,302,577.
It was subsequently discovered that CSA, CSC and mixtures thereof, have a unique and very different therapeutic use.
This use addresses the problem of organ and tissue transplant rejection by the human host, and the somewhat similar problem relating to inanimate implants such as tooth implants, hip prosthesis, intraocular implant, heart valve, etc.
Transplant and implant rejection phenomena is believed to be associated with the immune system of the body, physiologic inflammatory processes, surgical procedures, mechanical interactions or a combination thereof
|
| Related patents |
|
|
Painless electrolyte solutions
What is claimed is: 1. A composition consisting of: (a) electrolytes selected from the group consisting of K.sup.+, Ca.sup.++, Na.sup.+ and Mg.sup.++ salts of anions, ...
|
|
|
Method for enhancing healing of corneal endothelial wounds
Method using a non-steroidal antiinflammatory compound, such as indomethacin, and/or a growth factor that causes a change in cell function when bound to a cell surface ...
|
|
|
Method and agents for promoting wound healing
In accordance with the present invention, diagnostic and therapeutic protocols are proposed that are predicated in part on the discovery that certain cytokines have been ...
|
|
|
Control of post-surgical intraocular pressure using clonidine derivatives
OF THE INVENTION The present invention utilizes certain clonidine derivatives, as defined above, to control intraocular pressure of the eye during invasive or non-...
|
|
|
Tissue irrigating solution
OF THE PREFERRED EMBODIMENTS The present invention is directed generally to an improved technique for packaging a tissue irrigating solution of the type which includes ...
|
|
|
Indolyl substituted hydroxylamine derivatives
OF THE INVENTION More particularly the invention relates to the compounds of formula I ##STR2## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub....
|
|
|
Prevention of synovial adhesions
OF THE INVENTION A wide variety of lipid particles may include a nonsteroidal antiinflammatory agent to form the vesicles of the invention, which are capable of ...
|
|
|
Method for reducing unwanted cellular adhesions
In accordance with one aspect of the present invention there is provided a method for reducing undesired cell adhesions at a compromised site. The method involves ...
|
|
|
Anti-infective and anti-inflammatory releasing systems for medical devices
Devices are provided having a polymer coating incorporating compounds inhibiting inflammation and infection, along with subsequent tissue growth onto and around the ...
|
|
|
Combined use of dopamine and serotonin agonists in the treatment of immune disorders
What is claimed is: 1. A method of treating a disorder to the immune system selected from the group consisting of fibromyalgia and chronic fatigue syndrome comprising ...
|
|
|
Drugs 
